Print

Intercept Pharmaceuticals Appoints Daniel Regan as Chief Commercial Officer  
3/4/2013 11:25:05 AM

NEW YORK, March 4, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced the appointment of Daniel P. Regan to the newly created position of Chief Commercial Officer. Mr. Regan is a seasoned commercial executive bringing more than 20 years of pharmaceutical and biotechnology industry experience to the company.
//-->